MAM
AMRX icon

Martingale Asset Management’s Amneal Pharmaceuticals AMRX Stock Holding History

Martingale Asset Management’s Portfolio AMRX Stock Details AMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.9M Buy
283,033
+22,722
+9% +$311K 0.12% 188
2026
Q1 		$3.24M Buy
260,311
+50,465
+24% +$678K 0.08% 240
2025
Q4 		$2.64M Buy
209,846
+9,643
+5% +$110K 0.07% 259
2025
Q3 		$2M Buy
200,203
+45,916
+30% +$412K 0.05% 317
2025
Q2 		$1.25M Buy
154,287
+2
+0% +$15 0.03% 416
2025
Q1 		$1.29M Buy
154,285
+4,637
+3% +$38.7K 0.03% 400
2024
Q4 		$1.19M Buy
149,648
+53,944
+56% +$453K 0.03% 435
2024
Q3 		$796K Buy
95,704
+21
+0% +$164 0.02% 522
2024
Q2 		$608K Hold
95,683
– – 0.01% 563
2024
Q1 		$580K Buy
+95,683
New +$540K 0.01% 591

Other funds holding AMRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Martingale Asset Management's AMRX Position: Q2 2026 in Review

Martingale Asset Management increased its Amneal Pharmaceuticals (AMRX) stake by 8.7% in Q2 2026, buying an estimated $311K and bringing the position to 283,033 shares worth $4.9M. The position accounts for 0.12% of the portfolio, ranked #188.

Martingale Asset Management first reported a position in AMRX in Q1 2024 and has held it in 10 quarters since. 311 funds tracked by Wall St. Rank hold AMRX as of Q2 2026.

  • Martingale Asset Management held 283,033 shares of Amneal Pharmaceuticals worth $4.9M as of Q2 2026.
  • Martingale Asset Management bought 22,722 Amneal Pharmaceuticals shares in Q2 2026, an estimated $311K.
  • Amneal Pharmaceuticals made up 0.12% of Martingale Asset Management's portfolio in Q2 2026, its #188 holding.
  • Martingale Asset Management first reported a position in Amneal Pharmaceuticals in Q1 2024 and has held it in 10 quarters since.
  • 311 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q2 2026.

Based on Martingale Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.